▼ Summary
– The FDA has approved a daily pill version of the weight-loss drug Wegovy, which contains the same active ingredient (semaglutide) as the existing weekly injection.
– In clinical trials, the pill achieved significant average weight loss (13.6%) and improved cardiovascular risk factors, with nearly 30% of participants losing over 20% of their weight.
– The pill is a higher-dose version of Novo Nordisk’s earlier oral diabetes drug Rybelsus, as greater doses are required to achieve full weight-loss efficacy for obesity.
– While offering a convenient alternative to injections, the pill’s effectiveness depends on daily adherence, with ideal use yielding results similar to the injectable version.
– The pill will be available starting in early January at a listed price of $149 per month, with production underway to meet anticipated U.S. demand.
The U.S. Food and Drug Administration has approved a daily pill form of the popular weight-loss medication Wegovy, offering a new option for individuals managing obesity. This oral version, developed by Novo Nordisk, contains the same active ingredient, semaglutide, as the company’s established weekly injection. The approval provides a significant alternative for patients who may prefer a tablet over an injectable format, expanding access and choice in a rapidly growing therapeutic area.
Martin Holst Lange, chief scientific officer at Novo Nordisk, emphasized the importance of patient choice, stating this development allows those seeking weight loss to select between a weekly injection or a daily tablet. The race to create effective pill versions of GLP-1 drugs has intensified as their popularity soars, with these medications working by mimicking a natural hormone that acts on the brain and gut to increase feelings of fullness.
Clinical data supporting the approval, published in the New England Journal of Medicine, demonstrated substantial results. Participants taking the daily pill achieved an average weight loss of 13.6 percent over 64 weeks. Notably, nearly 30 percent of study participants lost 20 percent or more of their body weight. The research also indicated improvements in cardiovascular disease risk factors and physical activity levels comparable to those seen with the injectable form of Wegovy.
While pills can offer greater convenience, their effectiveness relies heavily on consistent daily use, which can be a challenge. Trial investigators noted that if participants took the medication perfectly as prescribed, the projected average weight loss would be 16.6 percent, a figure on par with the injectable version’s results. This highlights the critical role of adherence in achieving optimal outcomes with any medication.
This is not Novo Nordisk’s first oral semaglutide product. The company previously gained approval for Rybelsus in 2019 for treating type 2 diabetes. However, that medication was never approved for chronic weight management and is less effective for weight loss than newer GLP-1 drugs. The newly approved Wegovy pill is essentially a higher-dose formulation of Rybelsus. The efficacy for the obesity pill is driven by dose, explained Lange, noting that higher doses are necessary to realize full weight-loss potential. The Wegovy pill is prescribed at 25 milligrams, while Rybelsus is a 14-milligram tablet.
Common side effects for the oral form include nausea and vomiting, mirroring the known side-effect profile of the injectable Wegovy. On the commercial front, Novo Nordisk announced the starting dose of 1.5 milligrams will be available in early January at a list price of $149 per month, with potential savings offers available. The company has already initiated production at its U.S. manufacturing facilities and expects to have sufficient supply to meet initial demand in the American market.
(Source: Wired)
